Pliant Therapeutics (NASDAQ:PLRX) Price Target Cut to $1.50 by Analysts at Citigroup
Pliant Therapeutics (NASDAQ:PLRX – Free Report) had its price objective lowered by Citigroup from $4.00 to $1.50 in a report ...
Pliant Therapeutics (NASDAQ:PLRX) Rating Lowered to “Hold” at Stifel Nicolaus
Pliant Therapeutics (NASDAQ:PLRX – Get Free Report) was downgraded by equities research analysts at Stifel Nicolaus from a “buy” rating to a “hold” rating in a research note issued on Monday, ...
The Pharma Letter13h
Pliant halts lung fibrosis trial amid safety concerns
Pliant Therapeutics has scrapped its Phase IIb Beacon-IPF trial for bexotegrast in idiopathic pulmonary fibrosis (IPF), after ...
Biotech Alert: Searches spiking for these stocks today
These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include: ...